IMW 2021 | Pfizer Medical Information - Gulf Countries (UAE, Oman, Bahrain, Qatar, Kuwait)

Congress Materials

Medical Information

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait

Select I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait

I am a patient / caregiverNo, go back to the patient portal

Select I am a patient / caregiverNo, go back to the patient portal

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.

Back to Congresses

Oral Presentation

Dholaria B, Bahlis NJ, Raje NS, Costello CL, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Lon HK, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM September 8, 2021 IMW 2021 Hematology

MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)

View Presentation View Abstract Plain Language Summary